In this population, a hemoglobin response was attained by 46% of the patients receiving 200 mg of etavopivat, 33% of those on 400 mg, and by 13% of those given a placebo. Most reported adverse events ...
Thomas W. LeBlanc, MD, MA, discusses how erythroid maturation agents (EMAs), such as luspatercept, are increasingly important in the anemia management landscape for low-risk myelodysplastic syndromes ...